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Historical medical recordings as early as 2500 BC referred
to the practice of Prevention. References to the importance
of prevention are found in the writings of Hippocrates and
Osler, thus rendering the prevention concept important and
certainly “not new” in the practice of medicine (1). Previous
Bethesda Conferences 11 (1980) (2) and 27 (1995) (3)
addressed Prevention of Cardiovascular Diseases; however,
to date, Preventive Cardiology has yet to establish an
appropriately strong position in the overall care of patients
with cardiovascular disease (CVD).
“Bethesda Conference 33—Preventive Cardiology: How
Can We Do Better?” evolved to address specific issues and
provide precise recommendations to better implement the
prevention of CVD, which is the number one cause of death
and disability in the U.S. today. Five task forces of writers
and participants with various expertise provided in-depth
reports on numerous aspects of preventive cardiology. The
following paragraphs cite salient points extracted and para-
phrased from each task force.
The first task force addresses in finite detail the magni-
tude of the overall problem and the opportunities and
challenges involved. Cardiovascular disease (CVD) is the
leading cause of death and disability; it is increasing in
prevalence in many regions of the world; and it includes all
ethnic, racial, and gender groups. Risk factors that predis-
pose to CVD have been identified, the modification or
alteration of which can result in a significant decrease in
morbidity and mortality for CVD. Risk factor categories
now addressed are genetic (e.g., abnormal lipids), second
level (e.g., endothelial dysfunction), and acute (e.g., plaque
rupture perhaps related to nicotine). Obesity and diabetes
are emerging as major risks and are increasing in prevalence
in America. Primordial prevention (or prevention of risk
factors) is being emphasized. These strategies address
proper exercise and diet and should focus on early school
years. A public health approach to CVD prevention is
needed and may require public policy changes and aggres-
sive marketing to the public. An ongoing perceived problem
is that “sick care” may not mix well with preventive care.
The second task force considers the cost of prevention:
can we afford it; can we afford not to do it? As emphasized,
prevention guidelines should reflect economic impacts and
value from a societal perspective. As such, a society with
limited resources should determine which interventions
have the most value. Cost-effectiveness analysis is the most
often used approach for economic evaluation of a medical or
health care strategy. In concert with this and a “fixed”
monetary allocation for health, policy makers want the
greatest return on their investment. For example, studies of
smoking cessation intervention suggest that cost per year of
life saved is small compared with other interventions. In
addition, assuming that sedentary behavior increases the risk
of CVD by 1.9-fold, $6.4 billion would be saved if all of
America began to walk regularly. The prevention of death
from one disease may not be a valuable outcome if overall
life expectancy is not changed because of another significant
illness. An obstacle in an investment in prevention is the
public expectation that such an investment should pay for
itself.
The third task force discusses “Getting Results: Who,
Where, and How?” This component encourages the prop-
osition that physician encounters with patients be broad-
ened to include non-physician personnel and community
resources. A combination of community programs, medical
referrals and therapy, and mass media for screening and
treatment will decrease risk factor levels and CVD. Indus-
tries have been supportive of prevention when and if their
interests are in accord with national and local organizational
guidelines to change knowledge, attitudes, beliefs, and
behavior. Community programs involve three models: clin-
ical, public health, and health promotion. Momentum and
sustained interventions are crucial to the success with
community programs. Case management is effective and
involves a nurse in the clinical setting to coordinate the
determination of the risk with the treatment plan to reduce
risk. In this setting, the guidelines should include outcome
assessment and quality assurance. Barriers to implementa-
tion of preventive cardiology in medical settings include
economics, lack of interest in the patient, and lack of skill
and/or motivation of the provider.
The fourth task force addresses adherence issues and
behavioral changes and how to achieve a long-term solution.
Evidence is presented supporting the involvement of other
health care professionals (especially nurses) in treatment
plans to improve effectiveness of preventive interventions
and increase overall adherence. Brief provider intervention
can have a positive effect on adherence. A critical time to
target adherence strategies is the early phase of treatment,
realizing that poor adherence is higher in those with three or
more comorbidities. Awareness of how people reason is
important in adherence. Consideration of the stages of
change—pre-contemplation, contemplation, preparation,
action, and maintenance—which reflect steps of any behav-
ioral intervention process is important in the process.
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Another important theoretical approach is the social cogni-
tive theoretical model. Ecological frameworks recognize
that human behavior is influenced by intrapersonal, inter-
personal, institutional, and community factors as well as
public policy.
The fifth task force discusses the role of the cardiovascu-
lar (CV) specialist in prevention—trainee to champion.
Substantial data confirms that prevention is not taught in
most medical schools and less than one-third of CV
specialty training programs have formal preventive cardiol-
ogy. Limited time, lack of curriculum integration, lack of
trainee interest, and the focus on critical care are all barriers.
A solution is to build prevention-related objectives into
global medical curriculum reform with associated faculty
development activity. Both cognitive and applied systems
training are needed to prepare specialists to establish pre-
vention programs. One problem is that CV specialists
typically address the chief complaint and often leave pre-
vention to the primary referral. Cardiovascular specialists
must address primary prevention and risk factor control and
should use a team approach. Physician advice is especially
helpful with diet and exercise. Use of evidence-based
prompts and alerts can help guide adherence. In addition,
health care system changes and informatics can be valuable
in the process. A CV specialist should be a “champion” for
prevention. Ideally, such a specialist should have clinical
training with a Masters in public health and/or expertise in
outcomes research.
In summary, the five task forces have addressed the major
concerns in preventive cardiology. The recommendations
and in-depth consensus discussions that follow will provide
the reader with a thorough understanding of the issues that
prevail today in this vastly important domain of health care.
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Summary Recommendations—
Preventive Cardiology: How Can We Do Better?
Cardiovascular disease (CVD) prevention can play a dy-
namic and important role in combating the leading cause of
disability and death in America today. The summary rec-
ommendations that follow reflect the detailed and resource-
ful work of the writing groups and participants of the
American College of Cardiology (ACC) 33rd Bethesda
Conference—Preventive Cardiology: How Can We Do
Better? These recommendations highlight the research,
funding, policy, and clinical–educational changes needed to
effectively implement preventive cardiology in the existing
health care system of America.
RESEARCH
● Support intensive research to determine which strategies
are most effective in promoting healthy lifestyles and
adherence to CVD prevention in the community, in
health care organizations, by providers, and by patients in
a variety of clinical care settings.
● Promote studies that translate efficacy research into
effectiveness trials and community-based demonstration
projects in ethnically, geographically, and economically
diverse groups. These studies should examine the biases,
selection problems, unrealistic intervention intensity, and
sequence effects that result in study outcomes failing to
translate into real-world outcomes.
● Give a higher priority to research into understanding the
barriers associated with adherence to CVD prevention
guidelines at the community, health care provider, and
patient levels.
● Conduct studies of various risk-factor interventions, in-
cluding the manner in which interventions should be
sequenced with regard to the psychosocial state of the
patient (e.g., stage of change and motivation).
● Gain increased understanding of the extent to which
patient and provider beliefs, expectations, and preferences
influence provider-patient communication.
● Place special focus on vulnerable groups, including the
economically disadvantaged, the elderly, and ethnic mi-
norities.
● Encourage the development and testing of creative,
nontraditional ways to promote healthy life styles—such
as social marketing.
● Study the efficacy of policy and legal changes in reducing
CVD risk factors (e.g., tobacco taxes and mandated
school-based physical education programs).
● Increase research regarding the cost-effectiveness of
CVD prevention.
● Conduct further research to resolve measurement issues.
This applies not only to measurement of medication-
taking behavior but also to the ability to monitor and
verify behavior in other areas such as smoking, diet, and
physical activity.
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